Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2022-06-28 Major Shareholding Noti…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an FDA approval event for a plasma collection facility and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a certification or a proxy statement, nor does it relate to board changes, mergers, or dividends. Given the nature of the filing and the lack of detailed financial data, this fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories.
2022-06-27 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 21, 2022, reporting on the results of the company's 2022 Annual Meeting of Stockholders. It details the voting results on several proposals including election of directors, approval of an equity compensation plan, advisory approval of executive compensation, and ratification of the independent auditor. The document primarily provides official results from shareholder votes at a general meeting. There is no detailed financial report or earnings data, nor is it a proxy statement or a presentation. The key content is the submission of matters to a vote and the voting results. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6295 characters) and content support this classification with high confidence.
2022-06-21 English
15-12B
Regulatory Filings Classification · 100% confidence The document is a Form 15 filed with the SEC, which is a certification and notice of termination of registration under Section 12(g) of the Securities Exchange Act of 1934 or suspension of duty to file reports under Sections 13 and 15(d). It is a regulatory filing notifying the SEC and the public about the termination of reporting obligations. The document is short (2068 characters) and primarily serves as a certification and notice rather than a full financial report or detailed announcement. It does not contain financial statements or detailed analysis but is a formal regulatory notice. Therefore, it fits best under Regulatory Filings (RNS).
2022-06-16 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically reports the expiration of a Rights Agreement and the Board's decision not to renew it. There are no financial statements or detailed financial data presented, nor is this an announcement of an upcoming report. The document is short (2990 characters) and focuses on a corporate event rather than financial results or management discussion. This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-13 English
FORM 4
Director's Dealing
2022-05-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.